Healthcare provider profile · identity verified

Marko Dimiskovski, DO

Family Practice · SPRINGFIELD, PA · NPI 1609368687

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	223	73
Amlodipine Besylate	Amlodipine Besylate	119	44
Lisinopril	Lisinopril	117	35
Losartan Potassium	Losartan Potassium	116	30
Metoprolol Succinate	Metoprolol Succinate	112	27
Omeprazole	Omeprazole	112	30
Pantoprazole Sodium	Pantoprazole Sodium	112	32
Metformin Hcl	Metformin Hcl	92	31
Levothyroxine Sodium	Levothyroxine Sodium	89	24
Simvastatin	Simvastatin	89	23
Tamsulosin Hcl	Tamsulosin Hcl	89	23
Metformin Hcl Er	Metformin Hcl	71	19
Gabapentin	Gabapentin	70	30
Trazodone Hcl	Trazodone Hcl	68	24
Albuterol Sulfate Hfa	Albuterol Sulfate	67	29
Fluticasone Propionate	Fluticasone Propionate	66	35
Eliquis	Apixaban	59	17
Pravastatin Sodium	Pravastatin Sodium	59	18
Rosuvastatin Calcium	Rosuvastatin Calcium	59	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	52	23
Famotidine	Famotidine	52	20
Escitalopram Oxalate	Escitalopram Oxalate	51	14
Jardiance	Empagliflozin	51	17
Hydrochlorothiazide	Hydrochlorothiazide	47	14
Ezetimibe	Ezetimibe	44	12
Clopidogrel	Clopidogrel Bisulfate	43	13
Metoprolol Tartrate	Metoprolol Tartrate	42	14
Furosemide	Furosemide	41	14
Bupropion Xl	Bupropion Hcl	38	suppressed
Allopurinol	Allopurinol	37	suppressed
Naproxen	Naproxen	34	15
Atenolol	Atenolol	33	suppressed
Glipizide Er	Glipizide	33	11
Glimepiride	Glimepiride	32	suppressed
Clonazepam	Clonazepam	30	suppressed
Montelukast Sodium	Montelukast Sodium	30	14
Alendronate Sodium	Alendronate Sodium	29	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	29	suppressed
Sertraline Hcl	Sertraline Hcl	29	11
Citalopram Hbr	Citalopram Hydrobromide	28	11
Januvia	Sitagliptin Phosphate	27	suppressed
Baclofen	Baclofen	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Valsartan	Valsartan	22	suppressed
Buspirone Hcl	Buspirone Hcl	21	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	13
Digoxin	Digoxin	19	suppressed
Mometasone Furoate	Mometasone Furoate	19	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Ozempic	Semaglutide	17	suppressed
Meloxicam	Meloxicam	16	suppressed
Prednisone	Prednisone	16	suppressed
Tramadol Hcl	Tramadol Hcl	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	15
Bumetanide	Bumetanide	15	suppressed
Calcitriol	Calcitriol	15	suppressed
Carvedilol	Carvedilol	15	suppressed
Haloperidol	Haloperidol	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Benztropine Mesylate	Benztropine Mesylate	14	suppressed
Glipizide	Glipizide	14	suppressed
Methylprednisolone	Methylprednisolone	14	12
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Ramipril	Ramipril	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Duloxetine Hcl	Duloxetine Hcl	13	suppressed
Linzess	Linaclotide	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Torsemide	Torsemide	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Finasteride	Finasteride	11	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	11	suppressed
Methimazole	Methimazole	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error